Duration of Goserelin for Premenopausal Hormone Receptor-Positive Breast Cancer
Goserelin should be continued for 5 years when used for ovarian function suppression in premenopausal women with hormone receptor-positive breast cancer after definitive treatment. 1
Evidence-Based Duration
The optimal duration is 5 years based on the landmark SOFT and TEXT trials 2, 1. The 2024 NCCN guidelines explicitly state that "5 years optimal according to SOFT and TEXT trial" and note that "no efficacy or safety data to support prolonged OFS" 1. The 8-year disease-free survival data showed 85.4% with ovarian suppression plus tamoxifen versus 80.2% with tamoxifen alone, demonstrating sustained benefit through the full 5-year treatment period 1.
Minimum Treatment Duration
A minimum of 2 years of ovarian suppression should be completed if the full 5-year course cannot be tolerated 1. The ASTRRA trial demonstrated that even 2 years of ovarian suppression added to tamoxifen significantly improved disease-free survival compared to tamoxifen alone in patients who remained premenopausal after chemotherapy 3. The 5-year disease-free survival was 91.1% with 2 years of ovarian suppression versus 87.5% with tamoxifen alone (HR 0.69, p=0.033) 3.
Dosing Schedule Options
Goserelin can be administered as:
- 3.6 mg subcutaneously every 4 weeks, or
- 10.8 mg subcutaneously every 12 weeks 1
Both formulations achieve equivalent ovarian suppression, with the 10.8-mg 3-monthly depot demonstrating non-inferiority to the monthly 3.6-mg formulation in achieving postmenopausal estradiol levels (99.1% vs 95.3% suppression at Week 12) 4.
Important Clinical Considerations
Monitor estradiol and FSH/LH levels to confirm adequate ovarian suppression, particularly:
- In women under age 45
- Prior to the next dose of GnRH agonist
- If vaginal bleeding occurs (contact physician immediately as aromatase inhibitors can stimulate ovarian function) 1
After completing ovarian suppression: Premenopausal patients wishing to continue adjuvant endocrine therapy after stopping ovarian suppression should switch to tamoxifen alone 1. Normal ovarian function typically returns within 12 weeks after goserelin discontinuation 5.
Extended Duration Beyond 5 Years
There is no efficacy or safety data supporting ovarian suppression beyond 5 years 1. While a 2026 Chinese expert consensus suggests extended treatment "may be considered in selected high-risk patients" 6, this lacks supporting randomized trial data. The standard remains 5 years based on the evidence from SOFT and TEXT 2, 1.
Common Pitfall to Avoid
Do not confuse the duration of ovarian suppression (5 years) with the total duration of endocrine therapy. After completing 5 years of ovarian suppression, patients may continue tamoxifen alone if they remain premenopausal, with total endocrine therapy potentially extending to 10 years based on ATLAS trial data showing reduced recurrence with extended tamoxifen 1.